Gilead Sciences
$144.74Change from previous close: −1.87%Absolute change: −$2.76
At a glance
- Revenue growth
- +2.40%
- 2025 vs 2024
- Net income growth
- +1,672.92%
- 2025 vs 2024
- Net margin
- 28.9%
- 2024: 1.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3,573 | 2,544 | 3,327 | 4,108 | 827 | 1,757 | 2,975 | 4,309 | 1,325 | 2,219 | 2,169 | 1,755 |
| Depreciation and amortization | 698 | 689 | 687 | 686 | 691 | 696 | 693 | 690 | 694 | 690 | 688 | 684 |
| Capital expenditure | -140 | -117 | -205 | -147 | -107 | -104 | -147 | -141 | -130 | -105 | -215 | -122 |
| Investing cash flow | -10,347 | 1,770 | -1,835 | -427 | -2,116 | -415 | -225 | -710 | -307 | -2,207 | -727 | -229 |
| Financing cash flow | 2,344 | -4,239 | -1,263 | -1,489 | -1,567 | -3,426 | 2,260 | -1,379 | -2,953 | -1,361 | -1,099 | -1,519 |
| Dividends paid | -1,029 | -1,040 | -994 | -1,005 | -994 | -1,010 | -973 | -983 | -972 | -990 | -943 | -953 |
| Share repurchases | -355 | -419 | -230 | -435 | -527 | -730 | -350 | -300 | -100 | -400 | -150 | -300 |
| Debt issued | 4,085 | — | — | — | — | — | 3,464 | — | — | — | 1.0 | 1,979 |
| Debt repaid | -17.0 | -2,766 | -8.0 | -9.0 | -9.0 | -1,762 | -7.0 | -112 | -1,851 | — | — | -2,250 |
| Effect of exchange rates | -19.0 | -11.0 | 5.0 | -5.0 | 73.0 | 19.0 | -55.0 | 44.0 | -11.0 | -18.0 | 37.0 | -6.0 |
| Net change in cash | -4,450 | 65.0 | 234 | 2,186 | -2,783 | -2,065 | 4,955 | 2,264 | -1,946 | -1,367 | 380 | 1.0 |
| Free cash flow | 3,433 | 2,427 | 3,122 | 3,961 | 720 | 1,653 | 2,828 | 4,168 | 1,195 | 2,114 | 1,954 | 1,633 |
| Levered free cash flow | 2,811 | 1,513 | 2,471 | 2,960 | 533 | 1,119 | 2,958 | 3,781 | 1,703 | 1,261 | 1,598 | 1,519 |